Literature DB >> 20505985

Nanoparticles: a promising modality in the treatment of sarcomas.

Michiro Susa1, Lara Milane, Mansoor M Amiji, Francis J Hornicek, Zhenfeng Duan.   

Abstract

Improvements in surgical technique, chemotherapy, and radiotherapy have enhanced the prognosis of sarcoma patients, but have since reached a plateau in recent years. Novel approaches have been sought but with limited results. Nanomedicine offers solutions in diverse areas of sarcoma therapy including diagnosis and treatment. Several varieties of nanoparticles, including multifunctional nanoparticles, are available that localize the biodistribution of conventional chemotherapeutics to the tumor site. Also, nanoparticles loaded with chemotherapeutic drugs have the ability to overcome drug resistance which is a major obstacle impeding the progress of the treatment. Multifunctional nanoparticles, which have the potential to further augment the bioavailability of drugs, are being actively investigated. In this review, we will discuss the application of nanoparticles for improving the treatment of sarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505985     DOI: 10.1007/s11095-010-0173-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  134 in total

Review 1.  A fresh look at tumor immunosurveillance and immunotherapy.

Authors:  M J Smyth; D I Godfrey; J A Trapani
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

2.  Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule.

Authors:  P van der Valk; C K van Kalken; H Ketelaars; H J Broxterman; G Scheffer; C M Kuiper; T Tsuruo; J Lankelma; C J Meijer; H M Pinedo
Journal:  Ann Oncol       Date:  1990       Impact factor: 32.976

3.  Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles.

Authors:  Qing-Rong Chen; Lei Zhang; Paul W Luther; A James Mixson
Journal:  Nucleic Acids Res       Date:  2002-03-15       Impact factor: 16.971

4.  Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Authors:  Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

5.  Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects.

Authors:  Weibo Cai; Dong-Woon Shin; Kai Chen; Olivier Gheysens; Qizhen Cao; Shan X Wang; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  Nano Lett       Date:  2006-04       Impact factor: 11.189

6.  A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1.

Authors:  D D Stuart; G Y Kao; T M Allen
Journal:  Cancer Gene Ther       Date:  2000-03       Impact factor: 5.987

7.  Nanoparticles of biodegradable polymers for clinical administration of paclitaxel.

Authors:  Si-Shen Feng; Li Mu; Khin Yin Win; Guofeng Huang
Journal:  Curr Med Chem       Date:  2004-02       Impact factor: 4.530

8.  Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.

Authors:  Zhichao Zhou; Marcela F Bolontrade; Krishna Reddy; Xiaoping Duan; Hui Guan; Ling Yu; Daniel J Hicklin; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

9.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

Authors:  Yogesh B Patil; Suresh K Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  Biomaterials       Date:  2009-10-01       Impact factor: 12.479

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  5 in total

Review 1.  Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market.

Authors:  Michele F Oliveira; Pedro P G Guimarães; Alinne D M Gomes; Diego Suárez; Rubén D Sinisterra
Journal:  J Chem Biol       Date:  2012-11-30

Review 2.  Assessing the barriers to image-guided drug delivery.

Authors:  Gregory M Lanza; Chrit Moonen; James R Baker; Esther Chang; Zheng Cheng; Piotr Grodzinski; Katherine Ferrara; Kullervo Hynynen; Gary Kelloff; Yong-Eun Koo Lee; Anil K Patri; David Sept; Jan E Schnitzer; Bradford J Wood; Miqin Zhang; Gang Zheng; Keyvan Farahani
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-10-31

3.  p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.

Authors:  Shunan Ye; Jacson Shen; Edwin Choy; Cao Yang; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Chemother Pharmacol       Date:  2015-12-23       Impact factor: 3.333

Review 4.  Nanotechnology in orthopedics: a clinically oriented review.

Authors:  Walter Ryan Smith; Parke William Hudson; Brent Andrew Ponce; Sakthivel Rajan Rajaram Manoharan
Journal:  BMC Musculoskelet Disord       Date:  2018-03-02       Impact factor: 2.362

5.  Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma.

Authors:  Yibo Liu; Ligang Chen
Journal:  J Healthc Eng       Date:  2022-03-19       Impact factor: 2.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.